Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial

✍ Scribed by J. Herrstedt; W. Arpornwirat; I. Albert; V.L. Hansen; R.R. Bandekar; J. Levin; S.M. Grunberg

• Book ID: 119598300
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 74 KB
• Volume: 6
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(08)70808-5